Abstract
In a double-blind crossover trial sodium valproate or placebo was added to the existing anticonvulsant treatment of 20 patients with chronic uncontrolled epilepsy. Sodium valproate 1200 mg/day significantly reduced the frequency of both tonic-clonic and minor seizures in these patients. Only mild and transient side effects occurred (drowsiness, ataxia, and nausea), and these may have been due to the effect of adding sodium valproate to existing phenobarbitone or phenytoin treatment. Further controlled trials are needed to assess more fully the efficacy of this drug in various types of epilepsy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Jeavons P. M., Clark J. E. Sodium valproate in treatment of epilepsy. Br Med J. 1974 Jun 15;2(5919):584–586. doi: 10.1136/bmj.2.5919.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kugler J., Knörl G., Empt J. Die Behandlung therapieresistenter Epilepsien mit Dipropylacetat. Munch Med Wochenschr. 1973 Jun 8;115(23):1103–1108. [PubMed] [Google Scholar]
- MEUNIER H., CARRAZ G., NEUNIER Y., EYMARD P., AIMARD M. [Pharmacodynamic properties of N-dipropylacetic acid]. Therapie. 1963 Mar-Apr;18:435–438. [PubMed] [Google Scholar]
- Meinardi H. Clinical trials of anti-epileptic drugs. Psychiatr Neurol Neurochir. 1971 Mar-Apr;74(2):141–151. [PubMed] [Google Scholar]
- Schobben F., van der Kleijn E., Gabreëls F. J. Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol. 1975 Feb 28;8(2):97–105. doi: 10.1007/BF00561557. [DOI] [PubMed] [Google Scholar]
- Völzke E., Doose H. Dipropylacetate (Dépakine, Ergenyl) in the treatment of epilepsy. Epilepsia. 1973 Jun;14(2):185–193. doi: 10.1111/j.1528-1157.1973.tb03955.x. [DOI] [PubMed] [Google Scholar]